BONE-MARROW TRANSPLANTATION FOR PHILADELPHIA-CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA

Between 1986 and 1995, 19 patients with Philadelphia chromosome-positi ve (Ph+) acute lymphoblastic leukemia underwent 20 autologous (n = 9) or allogeneic (n = 11) blood or marrow transplant procedures in first (n = 12) or second (n = 3) remission, or in relapse (n = 5). Four pati ents died due to transplant-related causes, 11 relapsed at 3-39 months , one survives with disease which did not remit after transplant, and three are alive in continuous remission at 1, 26 and 65 months. Two of the relapsing patients are alive; one autografted patient after an al lograft in second remission and one allografted patient after a donor leukocyte infusion. The projected overall survival is 37.5% at 3 years and 12.5% at 5 years. The 3-year probabilities of relapse and disease -free survival for autografted patients are 65.9% and 25.6% respective ly, and for allografted patients, 63.4% and 21.8% respectively. The st age of the disease at the time of transplant or the type of transplant did not affect the outcome significantly, and late relapses beyond 3 years were seen after allogeneic as well as autologous transplantation . In our experience, the outcome of patients with Ph+ acute lymphoblas tic leukemia continues to be poor despite high-dose therapy due to hig h relapse rates, and the development of additional measures to enhance the antileukemic efficacy of bone marrow transplantation is necessary .